Daiwa Securities Group Inc. Sells 8,783 Shares of Illumina, Inc. (NASDAQ:ILMN)

Daiwa Securities Group Inc. lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 76,058 shares of the life sciences company’s stock after selling 8,783 shares during the period. Daiwa Securities Group Inc.’s holdings in Illumina were worth $9,918,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC lifted its position in shares of Illumina by 91.7% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 4,199 shares of the life sciences company’s stock valued at $577,000 after acquiring an additional 2,009 shares during the period. SVB Wealth LLC boosted its position in shares of Illumina by 6.8% during the 1st quarter. SVB Wealth LLC now owns 3,277 shares of the life sciences company’s stock worth $450,000 after purchasing an additional 209 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Illumina by 0.4% in the 1st quarter. California State Teachers Retirement System now owns 253,629 shares of the life sciences company’s stock valued at $34,828,000 after buying an additional 1,064 shares during the period. Motley Fool Asset Management LLC increased its position in Illumina by 8.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 4,688 shares of the life sciences company’s stock valued at $644,000 after buying an additional 374 shares in the last quarter. Finally, Tidal Investments LLC raised its stake in Illumina by 51.2% during the 1st quarter. Tidal Investments LLC now owns 9,901 shares of the life sciences company’s stock worth $1,361,000 after buying an additional 3,352 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ILMN. TD Cowen raised their price objective on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Robert W. Baird boosted their price target on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. UBS Group upped their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Wednesday, August 28th. Finally, StockNews.com began coverage on shares of Illumina in a report on Thursday, August 29th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Stock Up 2.6 %

ILMN opened at $143.82 on Tuesday. Illumina, Inc. has a twelve month low of $93.51 and a twelve month high of $156.66. The company’s 50-day moving average price is $140.90 and its two-hundred day moving average price is $125.17. The stock has a market cap of $22.81 billion, a price-to-earnings ratio of -14.44 and a beta of 1.13. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the business earned $0.33 earnings per share. Illumina’s revenue for the quarter was down 3.5% on a year-over-year basis. As a group, equities analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.